Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants
- PMID: 11181904
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants
Abstract
The plasmalemmal dopamine (DA) transporter (DAT) is a principal site of action for cocaine. This report presents the novel finding that in addition to inhibiting DAT function, cocaine administration rapidly alters vesicular DA transport. Specifically, cocaine treatment abruptly and reversibly increased both the V(max) of DA uptake and the B(max) of vesicular monoamine transporter-2 (VMAT-2) ligand (dihydrotetrabenazine) binding, as assessed ex vivo in purified rat striatal synaptic vesicles. Selective inhibitors of the DAT (amfonelic acid and GBR12935), but not the plasmalemmal serotonin transporter (fluoxetine), also increased vesicular DA uptake. Moreover, DA depletion resulting from administration of the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine had cocaine-like effects. Conversely, administration of the DA-releasing agent methamphetamine rapidly decreased vesicular uptake. Taken together, these data demonstrate for the first time ex vivo that cocaine treatment rapidly alters vesicular monoamine transport, and suggest that alterations in cytoplasmic DA concentrations contribute to stimulant-induced changes in vesicular DA uptake. Hence, the VMAT-2 may be an important target for developing strategies to treat not only cocaine addiction but also other disorders involving alterations in neuronal DA disposition, including Parkinson's disease.
Similar articles
-
Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.J Pharmacol Exp Ther. 2001 Sep;298(3):1150-3. J Pharmacol Exp Ther. 2001. PMID: 11504813
-
Bupropion increases striatal vesicular monoamine transport.Neuropharmacology. 2005 Nov;49(6):820-30. doi: 10.1016/j.neuropharm.2005.05.004. Epub 2005 Jul 7. Neuropharmacology. 2005. PMID: 16005476
-
In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.J Pharmacol Exp Ther. 2000 May;293(2):329-35. J Pharmacol Exp Ther. 2000. PMID: 10772999
-
Rapid regulation of the dopamine transporter: role in stimulant addiction?Neuropharmacology. 2004;47 Suppl 1:80-91. doi: 10.1016/j.neuropharm.2004.07.010. Neuropharmacology. 2004. PMID: 15464127 Review.
-
[The dopamine transporter: characterization and physiopathologic implications].Encephale. 1995 Nov-Dec;21(6):445-51. Encephale. 1995. PMID: 8674469 Review. French.
Cited by
-
Oxytocin, a Novel Treatment for Methamphetamine Use Disorder.Neurol Int. 2022 Jan 30;14(1):186-198. doi: 10.3390/neurolint14010015. Neurol Int. 2022. PMID: 35225885 Free PMC article. Review.
-
Alterations in the Gut Microbiota of Rats Chronically Exposed to Volatilized Cocaine and Its Active Adulterants Caffeine and Phenacetin.Neurotox Res. 2019 Jan;35(1):111-121. doi: 10.1007/s12640-018-9936-9. Epub 2018 Jul 31. Neurotox Res. 2019. PMID: 30066173
-
Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.Med Res Rev. 2011 Jul;31(4):483-519. doi: 10.1002/med.20187. Epub 2010 Feb 4. Med Res Rev. 2011. PMID: 20135628 Free PMC article. Review.
-
Effects of prenatal methamphetamine exposure: a review of cognitive and neuroimaging studies.Metab Brain Dis. 2014 Jun;29(2):245-54. doi: 10.1007/s11011-013-9470-7. Epub 2013 Dec 28. Metab Brain Dis. 2014. PMID: 24370774 Review.
-
Functional and structural brain changes associated with methamphetamine abuse.Brain Sci. 2012 Oct 1;2(4):434-82. doi: 10.3390/brainsci2040434. Brain Sci. 2012. PMID: 24961256 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources